Luke Evnin, Ph.D.

Luke Evnin is managing director of MPM Capital, a venture firm dedicated to life sciences investing. Dr. Evnin co-founded MPM’s asset management business in 1997 to launch MPM’s first venture fund and established the San Francisco office for the firm in 1999. Previously, Dr. Evnin was at Accel Partners for over seven years including four as a General Partner.  At Accel Partners, he was involved in biopharmaceutical, medical device and healthcare service companies for Accel’s funds III, IV and V. Dr. Evnin earned his Ph.D. in the Department of Biochemistry at the University of California-San Francisco, and he received his A.B. in Molecular Biology magna cum laude from Princeton University. He serves on the External Advisory Board for QB3, the Advisory Board for Mission Bay Capital (the internal venture investment vehicle for QB3), the External Advisory Board for the Lewis Sigler Institute of Quantitative Genomics at Princeton, and is the Chairman of the Scleroderma Research Foundation.

Board of Directors

Peter Van Vlasselaer

Peter Van Vlasselaer, Ph.D.

Executive Chairman

Eric Moessinger

Eric Moessinger

NanoDimension

Mark McDade

Mark McDade

Qiming Venture Partners USA

Luke Evnin

Luke Evnin, Ph.D.

MPM Capital

Christian Richard

Christian Richard

Tekla Capital Management LLC

Jeanmarie Guenot

Jeanmarie Guenot, Ph.D.

Founder, President & CEO